Incyte Corporation [INCY]

Incyte Corporation is a biopharmaceutical firm engaged in the research development and global marketing of its own innovative therapies Its current product offerings include JAKAFI prescribed for myelofibrosis and polycythemia vera PEMAZYRE a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in various liquid and solid tumor types and ICLUSIG a kinase inhibitor utilized for chronic myeloid leukemia and Philadelphiachromosome positive acute lymphoblastic leukemia Beyond its marketed drugs Incytes pipeline features several promising candidates Among its clinicalstage assets are ruxolitinib targeting steroidrefractory chronic graftversushost disease GVHD and itacitinib which is undergoing Phase IIIII trials for newly diagnosed chronic GVHD Pemigatinib is also being investigated for conditions such as bladder cancer cholangiocarcinoma myeloproliferative syndrome and other tumor types Further advancing its research the company is developing Parsaclisib currently in Phase II studies for follicular lymphoma marginal zone lymphoma and mantle cell lymphoma Additionally Retifanlimab is in Phase II development for multiple indications including MSIhigh endometrial cancer Merkel cell carcinoma anal cancer and nonsmall cell lung cancer Incyte maintains a broad network of strategic alliances with numerous pharmaceutical and biotech companies including key partners like Novartis International Pharmaceutical Ltd Eli Lilly and Company and Agenus Inc among many others These collaborations extend to clinical trials notably joint efforts with MorphoSys AG and Xencor Inc to evaluate a combination therapy involving tafasitamab plamotamab and lenalidomide for patients with recurrent or resistant diffuse large Bcell lymphoma and follicular lymphoma Established in 1991 the corporations main offices are situated in Wilmington Delaware